Back to top
more

Align Technology (ALGN)

(Real Time Quote from BATS)

$212.55 USD

212.55
435,526

+1.77 (0.84%)

Updated Nov 5, 2024 03:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Illumina Offers FDA-Approved NGS Cancer Companion Test Kit

by Zacks Equity Research

Illumina, Inc. (ILMN) recently announced that its FDA-approved next-generation sequencing (NGS) -- Extended RAS Panel has met the Current Colorectal Cancer Guidelines.

    Lantheus Holdings at 52-Week High: What's Driving the Stock?

    by Zacks Equity Research

    Share price of Lantheus Holdings, Inc. (LNTH), based in North Billerica, U.S., scaled a new 52-week high of $17.85 on Jun 30, eventually closing a bit lower at $17.65.

      Envision Healthcare (EVHC) Acquires Anesthesia Associates

      by Zacks Equity Research

      Envision Healthcare Corporation (EVHC), recently announced that it has acquired Connecticut based anesthesia physician group practice, Anesthesia Associates of New London, P.C.

        Boston Scientific Rides on New Growth Plans amid Headwinds

        by Zacks Equity Research

        On Jun 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

          Abaxis (ABAX) Product Portfolio Strong, Competition Rife

          by Zacks Equity Research

          On Jun 28, we issued an updated research report on California-based Abaxis, Inc. (ABAX).

            BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag

            by Zacks Equity Research

            On Jun 28, we issued an updated research report on Elmsford, NY-based BioScrip, Inc. (BIOS), a leading Infusion Service provider.

              Walgreens (WBA) Tops Q3 Earnings, Scraps Rite-Aid Deal

              by Zacks Equity Research

              Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.33 in third-quarter fiscal 2017, up 12.7% year over year.

                Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes (Revised)

                by Zacks Equity Research

                Medtronic plc (MDT) inked a new outcomes-based collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.

                  Zimmer Biomet (ZBH) Launches X-Ray-Based X-PSI Knee System

                  by Zacks Equity Research

                  Zimmer Biomet Holdings, Inc. (ZBH) recently launched a X-ray-based Patient Specific Instrument, X-PSI Knee System.

                    Walgreens Boots-LabCorp Tie Up for Patient Service Centers

                    by Zacks Equity Research

                    Walgreens Boots Alliance, Inc. (WBA), a major pharmacy-led, health and wellbeing enterprise, recently announced collaboration with leading diagnostic service provider LabCorp (LH).

                      IDEXX Well-Poised on Strong Fundamentals, Global Growth

                      by Zacks Equity Research

                      On 29, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).

                        Quest Diagnostics to Buy Outreach Lab Service in Cape Cod

                        by Zacks Equity Research

                        Quest Diagnostics Inc. (DGX) recently teamed up with Cape Cod Healthcare (CCHC) to obtain its outreach laboratory service business.

                          Hologic (HOLX) Product Pipeline Strong, Competition Rife

                          by Zacks Equity Research

                          On Jun 27, we issued an updated research report on Hologic, Inc. (HOLX), headquartered in Bedford, MA.

                            NuVasive (NUVA) Grappling with Odds: Should You Dump Stock?

                            by Zacks Equity Research

                            On Jun 28, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA), a major player in the global spine market.

                              Ensign Group (ENSG) Acquires Facilities in Texas & Wisconsin

                              by Zacks Equity Research

                              The Ensign Group, Inc. (ENSG) recently announced that it acquired the real estate and operations of two assisted living facilities in Texas and three assisted living facilities in Wisconsin.

                                Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes

                                by Zacks Equity Research

                                Medtronic plc (MDT) recently inked a new 'outcomes-based' collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.

                                  Thermo Fisher Gets FDA's PMA for Oncomine Dx Target Test

                                  by Zacks Equity Research

                                  Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently received premarket approval (PMA) from the U.S. FDA for its Oncomine Dx Target Test.

                                    Walgreens (WBA) to Report Q3 Earnings: What's in Store?

                                    by Zacks Equity Research

                                    Walgreens Boots Alliance, Inc. (WBA) is slated to release third-quarter fiscal 2017 results before the market opens on Jun 29.

                                      Penumbra (PEN) at 52-Week High: What's Driving the Stock?

                                      by Zacks Equity Research

                                      Share price of Penumbra, Inc. (PEN), headquartered in Alameda, CA, scaled a new 52-week high of $91 on Jun 26, eventually closing a little lower at $86.95.

                                        Quest Diagnostics Enhances Blueprint for Athletes Service

                                        by Zacks Equity Research

                                        Quest Diagnostics Inc. (DGX), a global provider of clinical lab services, recently expanded its biomarker testing service known as Blueprint for Athletes.

                                          Why Investors Should Buy Align Technology (ALGN) Right Now

                                          by Zacks Equity Research

                                          Align Technology, Inc. (ALGN), the designer and manufacturer of Invisalign System, has rallied 51.9% over the last six months, ahead of the S&P 500's 7.9% gain.

                                            Cooper Companies (COO) Hits 52-Week High on Solid Prospects

                                            by Zacks Equity Research

                                            The Cooper Companies (COO) rallied to a new 52-week high of $247.80 on Jun 22, closing a tad lower at $245.06.

                                              Why Hold Strategy is Apt for Thermo Fisher (TMO) Stock Now

                                              by Zacks Equity Research

                                              Thermo Fisher Scientific, Inc. (TMO) has rallied 13.5% over the past three months, ahead of the S&P 500's mere 4.3% gain.

                                                Here's Why Henry Schein is Worth Adding to Your Portfolio

                                                by Zacks Equity Research

                                                Over the last six months, Henry Schein Inc. (HSIC) was consistently trading ahead of the S&P 500 Index.

                                                  Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How

                                                  by Zacks Equity Research

                                                  Bio-Rad Laboratories, Inc. (BIO) has rallied 12.9% over the last three months, ahead of the S&P 500's 4.3% gain.